LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
СтатьяРандомизированное исследованиеКлиническое исследование I фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mabrouk Omar S, Tichler Ben, Arnold H Moore, Thoma Eva C, Alexanian Sara M, Chen Jingxian, Liu Tzu-Ying, Hirschhorn Beth, Llorens Arenas Roy, Annand John W, Kapadnis Unnati, Shomo Alan A, Glajch Kelly E, Ferber Kyle, Moroishi Yuka, Czerkowicz Julie, Inra Jennifer, Postuma Ronald B, Gurevich Tanya, Mir Pablo, Morris Huw R, Aldred Jason, Brodsky Matthew A, Ellenbogen Aaron, Larson Danielle, Tolleson Christopher M, Siderowf Andrew, Tzoulis Charalampos, Balaguer Ernest, Marti Maria J, Zhao Hien T, Kordasiewicz Holly B, Lane Roger, Hirst Warren D, Fradette Stephanie, Graham Danielle L
Аннотация
LRRK2 (encoding leucine-rich repeat kinase 2) variants are the most common genetic cause of Parkinson's disease (PD). Lowering LRRK2 levels and/or inhibiting LRRK2 activity may modify PD-associated neuropathology. BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation. REASON was a first-in-human randomized phase 1 study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal BIIB094 in patients with PD. In part A, 40 participants received single doses of BIIB094 10-150 mg or placebo. In part B, 42 participants, stratified by LRRK2 variant status, received four doses of BIIB094 40-120 mg or placebo every 4 weeks. Adverse events were reported by 64.5% (20/31) of participants in part A and by 84.8% (28/33) of participants in part B. The events were mainly mild to moderate and not dose limiting. No serious adverse events related to BIIB094 were reported in either part A or B. Systemic BIIB094 exposure increased with dose. Cerebrospinal fluid (CSF) LRRK2 and phosphorylated Rab10 levels were lowered by up to 59% and up to 50%, respectively, irrespective of LRRK2 variant status. Concomitant reductions in CSF lysosomal protein levels suggested a potential mechanism whereby LRRK2 therapeutics may impact underlying PD pathophysiology. ClinicalTrials.gov identifier, NCT03976349 ; EudraCT number, 2018-002995-42.